JPH06503084A - 芳香族アルデヒドおよびその誘導体、ならびに皮膚病および関節炎の治療に有用なそれらの医薬学的組成物 - Google Patents

芳香族アルデヒドおよびその誘導体、ならびに皮膚病および関節炎の治療に有用なそれらの医薬学的組成物

Info

Publication number: JPH06503084A
Authority: JP; Japan
Prior art keywords: group; formula; carbon atoms; alkyl; treatment
Prior art date: 1990-11-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP4500554A

Other languages

English (en)

Japanese (ja)

Inventor

バーレッツェン、ベルント

ペテルセン、エリク・オライ

ラーセン、ロルフ・オラヴ

ドーニッシュ、ジョン・マイケル

ラムダール、トマス

オフテブロ、レイダル

Original Assignee

ノルスク・ヒドロ・アクシェセルスカープ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-30

Filing date

1991-11-25

Publication date

1994-04-07

1991-11-25 Application filed by ノルスク・ヒドロ・アクシェセルスカープ filed Critical ノルスク・ヒドロ・アクシェセルスカープ

1994-04-07 Publication of JPH06503084A publication Critical patent/JPH06503084A/ja

Status Pending legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims description 28
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
206010003246 arthritis Diseases 0.000 title claims description 5
208000017520 skin disease Diseases 0.000 title description 4
150000003934 aromatic aldehydes Chemical class 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 26
125000000217 alkyl group Chemical group 0.000 claims description 19
125000004432 carbon atom Chemical group C* 0.000 claims description 18
-1 cyclic acetal Chemical class 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
230000004663 cell proliferation Effects 0.000 claims description 8
125000001424 substituent group Chemical group 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 claims description 4
150000007854 aminals Chemical class 0.000 claims description 4
125000003277 amino group Chemical group 0.000 claims description 4
125000004663 dialkyl amino group Chemical group 0.000 claims description 4
LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
206010039792 Seborrhoea Diseases 0.000 claims description 2
201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
206010042953 Systemic sclerosis Diseases 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 3
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 3
229910052760 oxygen Inorganic materials 0.000 claims 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
208000002874 Acne Vulgaris Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
206010000496 acne Diseases 0.000 claims 1
210000004027 cell Anatomy 0.000 description 56
238000001243 protein synthesis Methods 0.000 description 20
230000014616 translation Effects 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
230000022131 cell cycle Effects 0.000 description 12
230000000694 effects Effects 0.000 description 8
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
239000004474 valine Substances 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
230000032823 cell division Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
201000011510 cancer Diseases 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000012545 processing Methods 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
230000035508 accumulation Effects 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
208000025747 Rheumatic disease Diseases 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241000282994 Cervidae Species 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
239000002585 base Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000006369 cell cycle progression Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000001516 effect on protein Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
230000000394 mitotic effect Effects 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001360 synchronised effect Effects 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
230000010190 G1 phase Effects 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101710188301 Protein W Proteins 0.000 description 1
230000018199 S phase Effects 0.000 description 1
206010039580 Scar Diseases 0.000 description 1
241000212342 Sium Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
229940053991 aldehydes and derivative Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
208000037516 chromosome inversion disease Diseases 0.000 description 1
208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000037336 dry skin Effects 0.000 description 1
238000010410 dusting Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000035773 mitosis phase Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000004092 self-diagnosis Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
JLUAVHQVEFDQEO-ZKZAMAJLSA-M sodium;(2r)-4-hydroxy-5-oxo-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-3-olate Chemical compound [Na+].O1C(=O)C(O)=C([O-])[C@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 JLUAVHQVEFDQEO-ZKZAMAJLSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000017105 transposition Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

JP4500554A 1990-11-30 1991-11-25 芳香族アルデヒドおよびその誘導体、ならびに皮膚病および関節炎の治療に有用なそれらの医薬学的組成物 Pending JPH06503084A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB909026080A GB9026080D0 (en)	1990-11-30	1990-11-30	Pharmaceutical compositions
GB9026080.3		1990-11-30
PCT/NO1991/000147 WO1992009276A1 (fr)	1990-11-30	1991-11-25	Aldehydes aromatiques et leurs derives et compositions pharmaceutiques utiles pour le traitement des maladies de la peau et de l'arthrite

Publications (1)

Publication Number	Publication Date
JPH06503084A true JPH06503084A (ja)	1994-04-07

Family

ID=10686268

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4500554A Pending JPH06503084A (ja)	1990-11-30	1991-11-25	芳香族アルデヒドおよびその誘導体、ならびに皮膚病および関節炎の治療に有用なそれらの医薬学的組成物

Country Status (6)

Country	Link
EP (1)	EP0559728A1 (fr)
JP (1)	JPH06503084A (fr)
AU (1)	AU9035691A (fr)
CA (1)	CA2095334A1 (fr)
GB (1)	GB9026080D0 (fr)
WO (1)	WO1992009276A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO309815B1 (no) *	1999-07-05	2001-04-02	Norsk Hydro As	Derivater av 5-nitrofurfural
NZ552216A (en) *	2001-11-16	2008-07-31	Bioform Medical Inc	Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
US8246969B2 (en)	2001-11-16	2012-08-21	Skinmedica, Inc.	Compositions containing aromatic aldehydes and their use in treatments
EP1622554A4 (fr) *	2003-05-15	2008-01-02	Bioform Medical Inc	Compositions contenant un melange d'un agent pharmaceutique ou d'un agent cosmetique et d'un aldehyde aromatique de support de groupe oxy
EP2661264B1 (fr)	2011-01-07	2018-12-05	Allergan, Inc.	Compositions de modification de mélanine et procédés d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6256423A (ja) *	1985-09-06	1987-03-12	Kaken Pharmaceut Co Ltd	悪液質治療改善剤
US4874780A (en) *	1987-03-11	1989-10-17	Norsk Hydro A.S.	Anticancer compounds

1990
- 1990-11-30 GB GB909026080A patent/GB9026080D0/en active Pending
1991
- 1991-11-25 AU AU90356/91A patent/AU9035691A/en not_active Abandoned
- 1991-11-25 EP EP92900278A patent/EP0559728A1/fr not_active Withdrawn
- 1991-11-25 WO PCT/NO1991/000147 patent/WO1992009276A1/fr not_active Ceased
- 1991-11-25 JP JP4500554A patent/JPH06503084A/ja active Pending
- 1991-11-25 CA CA002095334A patent/CA2095334A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
GB9026080D0 (en)	1991-01-16
EP0559728A1 (fr)	1993-09-15
WO1992009276A1 (fr)	1992-06-11
AU9035691A (en)	1992-06-25
CA2095334A1 (fr)	1992-05-31

Publication	Publication Date	Title
AU673998B2 (en)	1996-12-05	Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US4980160A (en)	1990-12-25	Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
JPH05500219A (ja)	1993-01-21	酸化窒素生成又は内皮誘導弛緩因子に関連した全身系低血圧の阻害のためのアルギニン拮抗剤
US5049396A (en)	1991-09-17	Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment
JPH08508045A (ja)	1996-08-27	癌性疾患の予防および治療のための製剤組成物、ならびにその製造法
KR19990063880A (ko)	1999-07-26	프테린 유도체 함유 활성산소 제거제
JP4033936B2 (ja)	2008-01-16	一酸化窒素産生抑制剤
EP1491206B9 (fr)	2011-03-09	Utilisation de derives peptidiques pour l'induction de la differentiation cellulaire
KR100207356B1 (ko)	1999-07-15	암 전이 억제제
JPH06503084A (ja)	1994-04-07	芳香族アルデヒドおよびその誘導体、ならびに皮膚病および関節炎の治療に有用なそれらの医薬学的組成物
DE3786456T2 (de)	1994-02-03	Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen.
JPWO1996032101A1 (ja)	1997-07-29	癌転移抑制剤
US5374658A (en)	1994-12-20	Use of oxidized polyamines, especially NN'-bis-(3-propionaldehyde)-1-4-diaminobutane (spermine dialdehye) in graft treatment
US5534531A (en)	1996-07-09	Compounds
US4997852A (en)	1991-03-05	Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
CA2107371A1 (fr)	1992-10-02	Methode d'inhibition de la fibrose
JPH072672A (ja)	1995-01-06	抗菌性配合製剤
JPS5849315A (ja)	1983-03-23	抗腫瘍剤
CN113456643B (zh)	2022-04-01	一种含普那布林的药物组合及其应用
WO2024221689A1 (fr)	2024-10-31	Utilisation d'un inhibiteur double cible jak-hadc et d'un médicament pour le traitement de maladies cutanées inflammatoires
JP2836797B2 (ja)	1998-12-14	血小板減少症およびまたは白血球減少症治療剤
KR100356899B1 (ko)	2002-10-31	궤양성 대장염 및/또는 크론병 예방 및 치료제
Bulkacz et al.	1968	Thiophene analogs of sulfanilamide: Bacterial growth inhibitors
CA2052686A1 (fr)	1992-04-13	Utilisation d'un retinoide
AU6770996A (en)	1997-03-05	Nitric oxide synthase (nos) inhibitors